Cargando…

Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients

This phase I study in Japanese patients evaluated the safety, pharmacokinetics, and preliminary efficacy of palbociclib, a highly selective and reversible oral cyclin‐dependent kinase 4/6 inhibitor, as monotherapy for solid tumors (part 1) and combined with letrozole as first‐line treatment of postm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamura, Kenji, Mukai, Hirofumi, Naito, Yoichi, Yonemori, Kan, Kodaira, Makoto, Tanabe, Yuko, Yamamoto, Noboru, Osera, Shozo, Sasaki, Masaoki, Mori, Yuko, Hashigaki, Satoshi, Nagasawa, Takashi, Umeyama, Yoshiko, Yoshino, Takayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968608/ https://www.ncbi.nlm.nih.gov/pubmed/26991823 http://dx.doi.org/10.1111/cas.12932

Ejemplares similares

Neutropenia management with palbociclib in Japanese patients with advanced breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2019)

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients
por: Masuda, Norikazu, et al.
Publicado: (2018)

Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
por: Mukai, Hirofumi, et al.
Publicado: (2018)

Palbociclib in combination with letrozole as first‐line treatment for advanced breast cancer: A Japanese phase II study
por: Masuda, Norikazu, et al.
Publicado: (2018)

Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3
por: Masuda, Norikazu, et al.
Publicado: (2020)

Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2015)

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
por: Takahashi, Masato, et al.
Publicado: (2020)

Evaluation of the Association of Polymorphisms With Palbociclib‐Induced Neutropenia: Pharmacogenetic Analysis of PALOMA‐2/‐3
por: Iwata, Hiroji, et al.
Publicado: (2021)

Effect of food on the pharmacokinetics of TAS‐102 and its efficacy and safety in patients with advanced solid tumors
por: Yoshino, Takayuki, et al.
Publicado: (2016)

Pathological features of triple‐negative breast cancers that showed progressive disease during neoadjuvant chemotherapy
por: Tanabe, Yuko, et al.
Publicado: (2017)

Prospective Cohort Study of Palbociclib Treatment in Postmenopausal Patients With Unresectable and Metastatic Hormone Receptor-Positive Breast Cancer: Study Protocol for a CSPOR-BC Palbociclib Cohort Trial
por: Narui, Kazutaka, et al.
Publicado: (2022)

Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer
por: Sasaki, Akinori, et al.
Publicado: (2020)

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors
por: Tamura, Kenji, et al.
Publicado: (2016)

Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study
por: Kotani, Haruru, et al.
Publicado: (2022)

Palbociclib enhances activin‐SMAD‐induced cytostasis in estrogen receptor‐positive breast cancer
por: Harada, Mayumi, et al.
Publicado: (2018)

Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target
por: Ouyang, Zhengxiao, et al.
Publicado: (2019)

Ambra1 modulates the sensitivity of mantle cell lymphoma to palbociclib by regulating cyclin D1
por: Jiang, Zhiping, et al.
Publicado: (2023)

Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients
por: Vlenterie, Myrella, et al.
Publicado: (2016)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Correction: therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target
por: Ouyang, Zhengxiao, et al.
Publicado: (2023)

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
por: Turner, Nicholas C., et al.
Publicado: (2019)

Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein
por: Hernandez Maganhi, Stella, et al.
Publicado: (2017)

Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
por: Kanbayashi, Yuko, et al.
Publicado: (2021)

Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
por: Guarducci, Cristina, et al.
Publicado: (2018)

Cyclin-Dependent Kinase 4/6 Inhibitor (Palbociclib) Induced Aplastic Anemia in a Patient with Metastatic Breast Cancer
por: Nwabudike, Stanley Madu, et al.
Publicado: (2018)

The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter
por: Fu, Han, et al.
Publicado: (2022)

Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study
por: Im, Seock-Ah, et al.
Publicado: (2019)

Cisplatin and S‐1 for urachal carcinoma: A single‐institution case series
por: Urasaki, Tetsuya, et al.
Publicado: (2019)

Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review
por: Gao, Shan, et al.
Publicado: (2023)

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
por: Duan, Chenxin, et al.
Publicado: (2021)

Modulation of plant growth in vivo and identification of kinase substrates using an analog-sensitive variant of CYCLIN-DEPENDENT KINASE A;1
por: Harashima, Hirofumi, et al.
Publicado: (2016)

Safety and efficacy profile of cyclin‐dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta‐analysis of clinical trials
por: Guo, Linghong, et al.
Publicado: (2019)

Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor–positive Prostate and Breast Cancers
por: Tien, Amy H., et al.
Publicado: (2022)

Combination of palbociclib and radiotherapy for glioblastoma
por: Whittaker, Shane, et al.
Publicado: (2017)

Palbociclib-Induced Liver Failure
por: Atallah, Rami, et al.
Publicado: (2020)

An unusual reversible color change in a gastric lesion during real‐time endoscopy
por: Osera, Shozo, et al.
Publicado: (2020)

Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients
por: Tanabe, Yuko, et al.
Publicado: (2020)

Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma
por: Hsu, Cheng-Lung, et al.
Publicado: (2018)

Primary Yolk Sac Tumor of the Omentum: A Case Report and Literature Review
por: Harano, Kenichi, et al.
Publicado: (2012)

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_g49nlrfek24pbh37glc3oo6ee8